Hudson Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Hudson Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,700	Closed	-$207K	–	67
2024 Q4	$207K	Hold	1,700	–	–	0.06%	66
2024 Q3	$212K	Hold	1,700	–	–	0.07%	65
2024 Q2	$269K	Hold	1,700	–	–	0.09%	56
2024 Q1	$220K	Buy	+1,700	New	+$208K	0.08%	61
2023 Q4	–	Sell	-1,700	Closed	-$206K	–	71
2023 Q3	$206K	Buy	+1,700	New	+$192K	0.08%	61
2023 Q2	–	Sell	-1,500	Closed	-$207K	–	69
2023 Q1	$207K	Buy	+1,500	New	+$195K	0.08%	61
2021 Q1	–	Sell	-1,500	Closed	-$256K	–	69
2020 Q4	$256K	Hold	1,500	–	–	0.11%	57
2020 Q3	$211K	Hold	1,500	–	–	0.1%	60
2020 Q2	$241K	Buy	+1,500	New	+$204K	0.13%	65

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Hudson Capital Management's SRPT Position: Q1 2025 in Review

Hudson Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 1,700 shares — an estimated $207K sold.

Hudson Capital Management first reported a position in SRPT in Q2 2020 and held it in 9 quarters. The position peaked at $269K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Hudson Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Hudson Capital Management sold 1,700 Sarepta Therapeutics shares in Q1 2025, an estimated $207K.
Hudson Capital Management first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 9 quarters.
Hudson Capital Management's Sarepta Therapeutics position peaked at $269K in Q2 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Hudson Capital Management's 13F filing for Q1 2025, filed 11 Apr 2025.